TOKYO–(BUSINESS WIRE)–Elix, Inc., an AI drug discovery firm with the mission of “Rethinking Drug Discovery” (CEO: Shinya Yuki/Headquarters: Tokyo; hereafter referred to as “Elix”) launched “Elix Discovery™,” the solely all-in-one platform that gives the whole lot wanted for AI drug discovery, from fashions for property prediction and molecular design to AI consulting and implementation assist.
Drug discovery utilizing synthetic intelligence (AI) and machine studying is attracting consideration to shorten the time required for drug discovery, cut back related prices, and enhance success charges. However, pharmaceutical firms face main boundaries in the adoption of AI due to inadequate data of AI expertise, problem in understanding how to use current AI instruments, lack of an intuitive and built-in platform, and the want to take into account the finest approach to make the most of AI for every particular drug discovery venture.
Elix Discovery™ is the solely all-in-one platform that gives a big selection of AI fashions, intuitive Graphical User Interface (GUI), skilled implementation assist and consulting, and data for AI drug discovery. The platform offers important options for AI drug discovery, and will proceed to develop from ongoing updates as new developments are made in the ever-evolving AI subject. While many AI firms are secretive and don’t disclose their data and strategies to shoppers, Elix, Inc. values transparency and brazenly shares data with our shoppers to assist them accumulate expertise in AI drug discovery.
Key modules of Elix Discovery™
Elix Predict (property prediction): By inputting the chemical compound construction into AI fashions, key details about the compound could be predicted, corresponding to exercise towards a goal, physicochemical properties, and ADMET properties.
Elix Create (molecular design): Generative AI fashions make it attainable to algorithmically create compounds with desired properties. Molecules could be optimized for quite a lot of elements, together with goal exercise, physicochemical properties, ADMET, and ease of synthesis. Predictive fashions from Elix Predict may also be simply used for molecular optimization thanks to built-in design of Elix Discovery™.
Elix Assist (lively studying): A collection of strategies for effectively coaching AI fashions when there may be little or no out there experimental information. Active studying primarily based on predictive AI fashions is used to recommend the compounds that needs to be used to acquire the subsequent set of experimental information primarily based on an optimization algorithm, thereby enabling the coaching of excessive performing fashions with fewer experiments.
Features of Elix Discovery™
An all-in-one platform to streamline drug discovery
Pharmaceutical firms want a number of varieties of AI fashions and information processing capabilities to conduct AI drug discovery, and Elix Discovery™ is an all-in-one platform that implements these fashions and capabilities. From property prediction to molecular design, Elix Discovery™ has all the important capabilities for AI drug discovery, and offers them in a modular structure that permits customers to leverage these capabilities seamlessly throughout the platform.
Many pharmaceutical firms really feel the want to have their very own AI drug discovery platform. However, constructing the total system in-house entails quite a lot of difficulties, together with the a few years and giant prices required for growth, hiring and coaching of proficient engineers with experience in a number of fields, and the want for on-going updates and technical assist. By introducing Elix Discovery™, which has already been developed particularly for AI drug discovery and examined in the subject by current customers, a high-quality setting for AI drug discovery could be established in a brief time frame. Furthermore, the platform is constantly up to date, permitting for the simple and fast adoption of cutting-edge expertise in a quick altering subject.
Individualized consulting, assist, and know-how supplied by researchers and engineers
Pharmaceutical firms have been gradual to make the most of AI not solely due to the lack of superior AI instruments, but additionally a lack of knowledge about AI in particular, particular person conditions that happen in drug discovery. In instances the place pharmaceutical firms depend on consulting AI firms, it is probably not attainable to accumulate in-house experience.
Elix’s researchers, who’ve consulting expertise with quite a few firms, will present assist whereas brazenly sharing their data, from proposing options to particular points to lectures on how to use the platform and background data about AI and deep studying. For advanced points, Elix’s engineers will work on behalf of the shopper to create and analyze AI fashions, and present them in a format that may be reproduced by the shopper.
Even in pharmaceutical firms that make use of computational chemists, the small variety of such chemists limits the assist that they will present to medicinal chemists in the use of AI. Elix offers a whole, built-in platform and consulting service for AI drug discovery, together with the coaching of medicinal chemists who can make the most of AI by way of the Elix Discovery™ platform.
Drug discovery is under no circumstances a problem that may be solved by AI alone; the data of the medicinal chemist is critically vital. Elix Discovery™ is a platform developed with this philosophy in thoughts, and designed to let the medicinal chemist leverage the energy of AI and deep studying. Even medicinal chemists with restricted data of AI can use the system intuitively with out worrying about selecting AI parameters and different particulars thanks to an automatic optimization process when creating AI fashions. In addition, computational chemists who’re extra conversant in AI can carry out detailed configurations, and simply share the fashions they create on the platform with medicinal chemists for speedy use.
Kaken Pharmaceutical Co., Ltd. has concluded a contract to use the Elix Discovery™
Elix has already supplied the Elix Discovery™ platform to Kaken Pharmaceutical Co., Ltd. (President and Representative Director: Hiroyuki Horiuchi/Headquarters: Tokyo; hereinafter referred to as “Kaken”), and started consulting and supporting operations for AI drug discovery at its Drug Discovery Center (in Kyoto) in May 2022.
Kaken was established in 1948 with its roots in the Riken Foundation, which has produced many extraordinarily vital scientists in the historical past of Japanese science, together with Yoshio Nishina, thought-about the father of contemporary physics, in addition to Nobel Prize winners Hideki Yukawa and Shinichiro Tomonaga. Starting with manufacturing and sale of penicillin in the similar 12 months, Kaken has launched many moral medicine, together with Mentax, Fibrast, and, extra lately, Clenafin and Regroth, with specific energy in therapeutic areas corresponding to dermatology and orthopedics (https://www.kaken.co.jp/english/).
Elix will proceed to contribute to fixing challenges in drug discovery by the on-going growth of Elix Discovery™.
About Elix, Inc.
Elix, Inc. is an AI drug discovery firm with the mission of “Rethinking drug discovery.” We are growing our enterprise for pharmaceutical firms, universities, and analysis establishments by specializing in machine studying to cut back the huge value and time concerned in drug discovery and enhance its success price. Visit https://www.elix-inc.com/ for extra particulars.